{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:12Z","timestamp":1761895752791},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T00:00:00Z","timestamp":1390521600000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p>Our previous phase I\/II trial of pegylated liposomal doxorubicin (PLD), low\u2010dose dexamethasone, and lenalidomide in patients with relapsed and refractory myeloma showed an overall response rate of 75%, with 29% achieving\u2009\u2265\u2009VGPR. Here, we investigated this combination (PLD 30 or 40 mg\/m<jats:sup>2<\/jats:sup> intravenously, day 1; dexamethasone 40 mg orally, days 1\u20134; lenalidomide 25 mg orally, days 1\u201321; administered every 28 days) in a phase II study in patients with newly diagnosed symptomatic multiple myeloma to determine its efficacy and tolerability (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> NCT00617591). At best response, patients could proceed with high\u2010dose melphalan or with maintenance lenalidomide and dexamethasone. In 57 patients, we found that the overall response rate and rate of very good partial response and better on intent\u2010to\u2010treat, our primary endpoints, were 77.2% and 42.1%, respectively, with responses per the International Myeloma Working Group. Median progression\u2010free survival was 28 months (95% CI 18.1\u201334.8), with 1\u2010 and 2\u2010year overall survival rates of 98.1 and 79.6%. During induction, grade 3\/4 toxicities were neutropenia (49.1%), anemia (15.8%), thrombocytopenia (7%), fatigue (14%), febrile neutropenia (8.8%), and venous thromboembolic events (8.8%). During maintenance, grade 3\/4 toxicities were mainly hematologic. We found this combination to be active in patients with newly diagnosed myeloma, with results comparable to other lenalidomide\u2010based induction strategies without proteasome inhibition. In addition, maintenance therapy with lenalidomide was well tolerated. Am. J. Hematol. 89:62\u201367, 2014. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23587","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T03:58:52Z","timestamp":1379044732000},"page":"62-67","source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of pegylated liposomal doxorubicin, low\u2010dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma"],"prefix":"10.1002","volume":"89","author":[{"given":"Rachid C.","family":"Baz","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad A.","family":"Hussein","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u2010Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Finley","family":"Oliver","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Nardelli","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Nodzon","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Leonel","family":"Ochoa\u2010Bayona","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Dalton","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-450742"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-356063"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(10)70004-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.51"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl313"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.12.1568"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.889"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20405"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22053"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334755"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-303487"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky R","year":"2008","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23587","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:34:44Z","timestamp":1696606484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1002\/ajh.23587"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23587","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}